Q4 2023 · 13F-HR
ARCH Venture Management, LLCholdings as filed
Filed 2024-02-14 · accession 0001012975-24-000083
$163.5M
Reported value
7
Positions
2023-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 76155X100 | RVMD | REVOLUTION MEDICINES, INC. | $92.7M | 56.7% | 3,233,490 | Common | NONE |
| 92539P101 | — | VERVE THERAPEUTICS, INC. | $28.0M | 17.1% | 2,008,809 | Common | NONE |
| 29479A108 | ERAS | ERASCA, INC. | $23.5M | 14.4% | 11,055,554 | Common | NONE |
| 24823R105 | DNLI | DENALI THERAPEUTICS, INC. | $8.2M | 5.00% | 381,249 | Common | NONE |
| 38341P102 | GOSS | GOSSAMER BIO, INC. | $7.4M | 4.50% | 8,055,916 | Common | NONE |
| 91381U200 | UNBX | UNITY BIOTECHNOLOGY, INC. | $1.9M | 1.19% | 1,004,817 | Common | NONE |
| 82933R100 | — | SINGULAR GENOMICS SYSTEMS, INC. | $1.7M | 1.07% | 3,798,926 | Common | NONE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.